Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
InMed Pharmaceuticals (NASDAQ: INM) Names New Chief Financial Officer Investor Brand Network - Mon Feb 12, 10:43AM CST

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal,...

INM : 0.2670 (-4.61%)
QBTS : 1.4000 (+2.19%)
ZYME : 9.00 (-2.60%)
Zymeworks to Join NASDAQ Biotech Index Baystreet - Fri Dec 15, 2023

Zymeworks Inc. (NASDAQ: ZYME) gained ground Friday, as the clinical-stage biotechnology company developing ...

ZYME : 9.00 (-2.60%)
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty FinancialNewsMedia - Fri Sep 22, 2023

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 22, 2023 – USA News Group  –  Despite the potential federal funding challenges due to the recent debt ceiling...

RY : 104.30 (-0.30%)
RY.TO : 142.34 (-0.45%)
ONCY : 1.1800 (+0.85%)
ONC.TO : 1.62 (+1.25%)
JAZZ : 112.01 (-1.03%)
ZYME : 9.00 (-2.60%)
AMGN : 311.41 (+0.96%)
PTGX : 29.61 (+0.99%)
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty PR Newswire - Fri Sep 22, 2023

/PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer...

ONC.TO : 1.62 (+1.25%)
ONCY : 1.1800 (+0.85%)
ZYME : 9.00 (-2.60%)
JAZZ : 112.01 (-1.03%)
PTGX : 29.61 (+0.99%)
AMGN : 311.41 (+0.96%)
Pioneering Cancer Treatments Show Promising Progress Despite Fiscal Challenges BayStreet.ca - Wed Sep 20, 2023

USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious “Cancer...

RY : 104.30 (-0.30%)
RY.TO : 142.34 (-0.45%)
ONCY : 1.1800 (+0.85%)
ONC.TO : 1.62 (+1.25%)
JAZZ : 112.01 (-1.03%)
ZYME : 9.00 (-2.60%)
AMGN : 311.41 (+0.96%)
PTGX : 29.61 (+0.99%)
2 Biotech Stocks That Could Make You Richer Motley Fool - Fri Jul 14, 2023

These biotech companies are seeing a spike in revenue growth.

VYGR : 8.48 (unch)
ZYME : 9.00 (-2.60%)
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers PR Newswire - Fri Jun 2, 2023

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity,...

JAZZ : 112.01 (-1.03%)
ZYME : 9.00 (-2.60%)
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates Zacks - Mon May 8, 2023

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 42.19% and 307.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ZYME : 9.00 (-2.60%)
HALO : 43.82 (+0.48%)
Regeneron (REGN) Q1 Earnings and Revenues Top Estimates Zacks - Thu May 4, 2023

Regeneron (REGN) delivered earnings and revenue surprises of 9.08% and 8.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

REGN : 984.64 (+0.79%)
ZYME : 9.00 (-2.60%)
Will Zymeworks Inc. (ZYME) Report Negative Earnings Next Week? What You Should Know Zacks - Mon May 1, 2023

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZYME : 9.00 (-2.60%)
RARE : 40.97 (+0.02%)

Barchart Exclusives

3 Growth Stocks Under $200 to Buy and Hold Forever Barchart - Tue May 14, 2:11PM CDT
Even a small investment in the right stocks can result in significant wealth over time. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot